Showing XXX results across 3 categories.
A comprehensive report of the last ICH meeting that was held in La Hulpe (Brussels), Belgium on 1-6 June 2013 is now available on the ICH website under the SC Reports page.
The ICH Q3D Guideline for Elemental Impurities reached Step 2b of the ICH Process in July 2013 and now enters the consultation period (Step 3).
Celebrating a Refreshed and Revitalised New Visual Identity for MedDRA.
Furthering the discussions on structural changes and increased engagement of regulators globally that took place in San Diego in November 2012, the ICH SC agreed measures aimed at increased transparency.
“ICH Pursues its Reform and Takes Steps Towards Increased Transparency”
The MedDRA Management Board met in La Hulpe, Belgium on 1 - 2 June 2013.
MedDRA Management Board Continues to Facilitate Further Global Uptake of MedDRA.
The ICH M7 Guideline on Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk reached Step 2 of the ICH Process in February 2013 and now enters the consultation period (Step 3).